OncoMatch/Clinical Trials/NCT03587844
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Is NCT03587844 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including brentuximab vedotin and brentuximab vedotin for mycosis fungoides.
Treatment: brentuximab vedotin · brentuximab vedotin · brentuximab vedotin — The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: CD30 negative
Disease stage
Required: Stage IB OR HIGHER
disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: brentuximab vedotin (brentuximab vedotin)
Exception: Cohort 2 patients eligible if previously treated; Cohort 1 patients excluded if previously treated
For Cohort 1, patients who have not received brentuximab vedotin are eligible. For Cohort 2, patients who have previously had brentuximab vedotin for MF/SS are eligible. Patients previously treated on Cohort 1 who were discontinued due to toxicity are not eligible for Cohort 2. Previous use of brentuximab vedotin (for Cohort 1 ONLY). For Cohort 2, patients who previously progressed on the standard 1.8mg/kg dose and schedule of brentuximab vedotin are ineligible.
Cannot have received: systemic anti-cancer therapy
Exception: must be discontinued at least 2 weeks prior to treatment
Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment.
Cannot have received: systemic therapy for another primary malignancy (other than T-cell lymphoma)
Exception: adjuvant or maintenance therapy for other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK Principal Investigator
Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma). Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK Principal Investigator.
Lab requirements
Kidney function
No severe renal impairment (CrCL <30 mL/min)
Liver function
No moderate or severe hepatic impairment (Child-Pugh B or C)
Severe renal impairment (CrCL <30 mL/min) [excluded]. Moderate or severe hepatic impairment (Child-Pugh B or Child-Pugh C) [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University Medical Center · Stanford, California
- Memorial Sloan Kettering Basking Ridge · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth · Middletown, New Jersey
- Memorial Sloan Kettering Bergen · Montvale, New Jersey
- Memorial Sloan Kettering Commack · Commack, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify